ClinicalTrials.gg
CompletedNCT02497716Updated Apr 16, 2019

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

A Phase 1 interventional study of Rivaroxaban (Xarelto, BAY59-7939 in Thrombosis, sponsored by Bayer. Completed at 21 sites in 8 countries. Open to participants aged 2 Months to 12 Years. Per ClinicalTrials.gov, last updated 2019-04-16.

Sponsored by Bayer · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was May 2018, 8 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
2 Months to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing rivaroxaban in Thrombosis — 4 open to participants now, 4 under way, 1 of them phase 3. Rivaroxaban · Thrombosis.

Enrollment
21st of 30
47 · median 84
Started
2015
with 2 others
Phase 1
7 of 30
1 open now
Registered
13th of 30
by date
Lead sponsor
5 of 30
Bayer

Among the 30 studies testing rivaroxaban in Thrombosis, this one is the 21st largest by enrollment, is one of 3 that started in 2015, is one of 7 in phase 1, and was the 13th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

4 of the 30 studies testing rivaroxaban in Thrombosis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 2 Months to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing rivaroxaban in Thrombosis, or all of them as a file.
02

Study summary

To characterize the pharmacokinetic profile of rivaroxaban administered as granules for suspension formulation and to document safety and tolerability

03

Conditions studied

  • Thrombosis

Browse trials for

04

Who can participate

Ages eligible
2 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children with an age ≥2 months and weight between 3 and \<12 kg, who have completed anticoagulant treatment at least 10 days prior to the planned study drug administration.

    • Gestational age at birth of at least 37 weeks
    • Oral feeding/ nasogastric/ gastric feeding for at least 10 days
  • Normal PT and within 10 days prior to planned study drug administration
  • Written provided and, if applicable, child assent provided

Exclusion criteria

Exclusion Criteria:

  • Active bleeding or high risk for bleeding, contraindicating anticoagulant therapy
  • Planned invasive procedures, including removal of central lines, within 24 hours before and after single dose intake
  • An estimate (eGFR) \< 30 mL/min/1.73m2
  • Hepatic disease which is associated either with:

    • coagulopathy leading to a bleeding risk, or (ALT) > 5x upper level of normal (), or
    • total > 2x ULN with direct bilirubin > 20% of the total.
  • count \< 50 x 10\^9/L
  • Hypertension (defined as systolic and/or diastolic blood pressure >95th percentile for age)
  • Concomitant use of strong inhibitors of both and P-glycoprotein, e.g., all protease inhibitors and the following azoleantimycotic agents: ketoconazole, itraconazole, voriconazole, and posaconazole, if used systemically (fluconazole is allowed)
  • Concomitant use of strong inducers of CYP3A4, e.g., rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine
  • Inability to cooperate with the study procedures
  • to rivaroxaban
  • Participation in a study with an drug other than rivaroxaban or a medical device within 30 days prior to treatment
  • History of gastrointestinal disease or surgery associated with impaired absorption
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Rivaroxaban

    Single arm, open label study

    Drug: Rivaroxaban (Xarelto, BAY59-7939

Interventions

06

What researchers measure

Primary outcomes

  1. AUC (area under the curve)

    Only PK will be tested in central lab

    Time frame: 4x within 8 hrs post study drug administrationh and 1x between 24-28h after administration

  2. Cmax (maximum observed drug concentration)

    Only PK will be tested in central lab

    Time frame: 4x within 8 hrs post study drug administrationh and 1x between 24-28h after administration

Secondary outcomes

  1. Prothrombin time (PT)

    Time frame: Pre-administration, if not done within the past 10 days, and then 24-28 hours after drug administration

  2. Activated partial thromboplastin time (aPTT)

    Time frame: Pre-administration, if not done within the past 10 days, and then 24-28 hours after drug administration

  3. Composite of major bleeding and clinically relevant non-major bleeding

    Time frame: From dose administration until follow up call on day 8+3

07

Study locations

21 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Children's Hospital Oakland
    Oakland, California 94609, United States
  • Riley Hospital For Children
    Indianapolis, Indiana 46202, United States
  • Carolinas Healthcare System
    Charlotte, North Carolina 28204, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205-2696, United States
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • McMaster Children's Hospital
    Hamilton, Ontario L8N 3Z5, Canada
  • Children's Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • HUS Lastenklinikka
    HUS, 00029, Finland
  • Turun yliopistollinen keskussairaala, kantasairaala
    Turku, 20520, Finland
  • Hôpital Arnaud de Villeneuve - Montpellier
    Montpellier, 34059, France
  • Hopital Necker les enfants malades - Paris
    Paris, 75015, France
  • University of Semmelweis/ Semmelweis Egyetem
    Budapest, 1094, Hungary
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, Lombardia 20122, Italy
  • A.O.U. Città della Salute e della Scienza di Torino
    Torino, Piemonte 10126, Italy
  • A.O. di Padova
    Padova, Veneto 35128, Italy
  • Hospital de Sant Joan de Déu
    Esplugues de LLobregat, Barcelona 08950, Spain
  • Ciutat Sanitària i Universitaria de la Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in May 2018, 30 months.

Of 30 phase 1 interventional studies under Thrombosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2015
First posted
Jul 14, 2015
StartActual
Nov 4, 2015
Primary completionActual
May 22, 2018
CompletionActual
May 22, 2018
Last update
Apr 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02497716
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 14, 2015
Start date
Nov 4, 2015
Primary completion
May 22, 2018
Completion
May 22, 2018
Last update
Apr 16, 2019

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion